Eric A. Harwood, Ph.D.
Eric Harwood's practice focuses on chemical, pharmaceutical, and life science patent prosecution, strategy, and diligence matters. Eric earned a B.S. in Chemistry from the University of California at Davis (summa cum laude), and M.S. and Ph.D. degrees in Organic Chemistry from the University of Washington in Seattle. He received a J.D. from the University of Washington School of Law.
Eric advises clients in patent matters in a wide variety of chemical industries, including early-stage drug candidates and FDA-approved products, nanostructured composite materials, heterogeneous catalysts and electroplated materials. Eric has successfully prosecuted Orange Book listed patents and assists clients in licensing and acquisition matters valued in the hundreds of millions of dollars in both the pharmaceutical and petrochemical industries. Eric especially enjoys understanding his client’s business objectives and then applying his expertise and experience in both patent law and chemistry to ensure those objectives are met. Prior to his career in law, Eric spent eight years working as both a medicinal and process chemist at small and multi-national pharmaceutical companies, where he designed and synthesized antibacterial, antiviral and kinase inhibitor drug candidates.
University of Washington School of Law
University of Washington
University of Washington
University of California, Davis
Eric is a member of the Washington State Bar and is registered to practice before the U.S. Patent and Trademark Office. He is a member of the Washington State Patent Law Association, the American Intellectual Property Law Association, and Life Science Washington. Eric volunteers for the local Juvenile Diabetes Research Foundation (JDRF), and is passionate about finding a cure and better treatments for those living with Type 1 diabetes.
Zhu, S., Harwood, E., Cai, S., Shang, X., Galvin, G., Jin, L., Yeung, A., Diaz, B., Zheng, M., Ryckman, D., “The Chemical Development ofCHIR-258” Chimia 60:584-592, 2006.
Edfeldt, F.N.B.; Harwood, E.A.; Sigurdsson, S.Th.; Hopkins, P.B.; Reid, B.R. “Solution Structure of a Nitrous Acid Induced DNA Interstrand Cross-Link” Nuc. Acid. Res. 32:2785-2794, 2004.
Edfeldt, F.N.B.; Harwood, E.A.; Sigurdsson, S.Th.; Hopkins, P.B.; Reid, B.R. “Sequence Context Effect on the Structure of Nitrous Acid Induced DNA Interstrand Cross-Links” Nuc. Acid. Res. 32:2795-2801, 2004.
Kline, T.; Andersen, N.H.; Harwood, E.A.; Bowman, J.; Malada, A.; Endsley, S.; Erwin, A.L.; Doyle, M.; Fong, S.; Harris, A.L.; Mendelsohn, B.; Mdluli, K.; Raetz, C.R.H.; Stover, C.K.; Witte, P.R.; Yabannavar, A.; Zhu, S. “Potent, Novel In-Vitro Inhibitors of the Pseudomonas Aeruginosa Deacetylase LpxC” J. Med. Chem. 45:3112-3129, 2002.
Okonogi, T.M.; Alley, S.C.; Harwood, E.A.; Hopkins, P.B.; Robinson, B.H. “Phosphate Backbone Neutralization Increases Duplex DNA Flexibility: A Model for Protein Binding” Proc. Nat. Acad. Sci. 99:4156-4160,2002.
Harwood, E.A.; Sigurdsson, S.Th.; Hopkins, P.B. “Chemical Synthesis of Cross-Link Lesions Found in Nitrous Acid Treated DNA: A General Method for the Preparation of N2-Substituted 2’-Deoxyguanosines” J. Org. Chem.65:2959-2964, 2000.
Harwood, E.A.; Sigurdsson, S.Th.; Edfelt, N.B.F.; Reid,B.R.; Hopkins, P.B. “Chemical Synthesis and Preliminary Structural Characterization of a Nitrous Acid Interstrand Cross-Linked Duplex DNA” J. Am.Chem. Soc. 121:5081-5082, 1999.
Kim, C.U.; McGee, L.R.; Krawczyk, S.H.; Harwood, E.A.; Harada, Y.; Swaminathan, S.; Bischofberger, N.; Chen, M.S.; Cherrington, J.M.; Xiang, S.F.; Griffen, L.; Cundy, K.C.; Lee, A.; Yu, B.; Gulnik, S.; Erickson,J.W. “New Series of Potent, Orally Bioavailable, Non-Peptidic Cyclic Sulfonesas HIV-1 Protease Inhibitors” J. Med. Chem. 39:3431-3434, 1996.
Casalnuovo, J.C.; Scott, R.W.; Harwood, E.A.; Schore, N.E. “First Example of Reversal of Normal Stereoselectivity in the Intramolecular Pauson-Khand Reaction” Tetrahedron Lett. 35:1153-1156, 1994.
Cai, S.; Chou, J.; Harwood, E.; Heise, C.; Machajewski, T.; Ryckman, D.; Shang, X.; Wiesmann, M.; Zhu, S. | Inhibition of FGFR3 and Treatment of Mulitple Myeloma. U.S. Pub. No.US2005/261307.
Cai, S.; Chou, J.; Harwood, E.; Heise, C.; Machajewski, T.; Ryckman, D.; Shang, X.; Wiesmann, M.; Zhu, S. | Preparation of Benzimidazole Quinolinones for Inhibiting FGFR3 and Treating Multiple Myeloma. PCT Pub. No. WO/2005/047244.
Cai, S.; Chou, J.; Harwood, E.; Ryckman, D.; Shang, X.; Zhu, S.; Machajewski, T. | Process for Preparation of Benzimidazolylquinolones by Reaction of Aminobenzonitriles with Benzimidazolylacetates. PCT Pub. No. WO/2005/046590.
Cai, S.; Chou, J.; Harwood, E.; Machajewski, T.; Ryckman, D.; Shang, X.; Zhu, S. | Preparation of Benzimidazole Quinolinones and Lactate Salts thereof for Inhibiting Vascular Endothelial Growth Factor Receptor Tyrosine Kinase. PCT Pub. No. WO/2005/046589.
Andersen, N.; Bowman, J.; Erwin, A.; Harwood, E.; Kline, T.; Mdluli, K.; Ng, S.; Pfister, K.; Shawar, R.; Wagman, A. | Preparation of Amino Acid Derivatives as Antibacterial Agents. PCT Pub. No. WO/2004/062601.
Machajewski, T.; Hannah, A.; Harwood, E.; Haroldsen, P.; Heise, C.; Samara, E.; Shang, X.; Vora, J.; Zhu, S. | Methods of Treating Cancer with a Methylpiperazinyl Benzimidazolyl Quinolinone and Related Methods. PCT Pub. No. WO/2004/043389.
Honors & Awards
Listed in The Best Lawyers in America®, 2021 & 2022
Selected to Washington Rising Stars®, 2012